Pfizer Limited announced the discontinuation of the marketing, distribution, and sale of its product, Minipress XL, effective September 7, 2026. This decision stems from Pfizer Inc. USA’s directive to cease the manufacture of the product. As a consequence, Pfizer Limited will receive a one-time payment of USD 13.9 Million (approximately Rs. 131.38 Crore) from its US-based parent company.
Product Discontinuation Announced
Pfizer Limited has informed stakeholders of a significant strategic decision: the company will cease the marketing, distribution, and sale of its product, Minipress XL. This discontinuation is set to take effect from September 7, 2026. The decision is a direct result of Pfizer Inc. USA’s move to discontinue the manufacture of Minipress XL globally.
Financial Implication for Pfizer Limited
In relation to this product discontinuation, Pfizer Limited is set to receive a substantial financial benefit. The company will be compensated with a lump-sum payment of USD 13.9 Million, which translates to approximately Rs. 131.38 Crore, from its parent entity, Pfizer Inc. USA. This payment reflects the financial settlement associated with ending the product’s lifecycle in the Indian market.
Source: BSE
